Illumina, Inc. $ILMN Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 523,448 shares of the life sciences company’s stock after selling 96,910 shares during the period. Teacher Retirement System of Texas owned 0.34% of Illumina worth $49,712,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its holdings in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the period. Quent Capital LLC purchased a new stake in Illumina in the third quarter valued at approximately $29,000. Cullen Frost Bankers Inc. acquired a new position in Illumina in the 2nd quarter worth approximately $41,000. NewSquare Capital LLC raised its position in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after buying an additional 369 shares during the last quarter. Finally, Mather Group LLC. acquired a new stake in Illumina during the 3rd quarter valued at approximately $46,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ILMN. Guggenheim increased their price objective on shares of Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Barclays increased their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Evercore ISI reissued an “outperform” rating and issued a $155.00 price objective on shares of Illumina in a report on Monday, January 5th. Canaccord Genuity Group upped their target price on Illumina from $112.00 to $130.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Finally, UBS Group lifted their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.47.

Illumina Stock Performance

NASDAQ ILMN opened at $153.95 on Friday. The stock has a market capitalization of $23.52 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 2.54 and a beta of 1.41. The stock has a 50-day moving average of $134.61 and a 200 day moving average of $112.77. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business earned $1.14 earnings per share. The business’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Scott Gottlieb bought 500 shares of Illumina stock in a transaction on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.